J&J Stock Leapfrogs 50-Day Line After Health Care Titan Raises Sales Outlook.

Autor:	GATLIN, ALLISON (AUTHOR)
Předmět:	JOHNSON & Johnson (Company), SALES forecasting, QUARTERLY reports, CORPORATE profits, WALL Street (New York, N.Y.), PORTFOLIO managers (Investments), BUSINESS revenue
Zdroj:	Investors Business Daily. 10/15/2024, pN.PAG-N.PAG. 1p.
Abstrakt:	Johnson & Johnson (JNJ) stock saw an increase after beating Wall Street's expectations for the third quarter, despite lowering its full-year profit forecast. The company's acquisition of V-Wave is expected to impact 2024 profits. However, J&J raised its sales outlook by $200 million. The stock is currently forming a flat base with a buy point at 168.85. Overall, J&J's third-quarter metrics exceeded analysts' expectations, with adjusted profit of $2.42 per share and sales of $22.5 billion. The company's innovative medicines business, particularly cancer treatments like Darzalex, contributed to its growth. However, J&J still faces numerous lawsuits related to its talc-based products. [Extracted from the article]
Databáze:	Regional Business News
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.